Position in EXEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,132,412
-$7,502,312 QoQ
Shares Held
142,980
-54.0% QoQ
Ownership
0.057%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
7 quarters on record
Voting authority
Sole 99.91047698978878.ToString("F0")%
Shared 0.ToString("F0")%
None 0.08952301021121835.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Clark Capital Management Group, Inc. holds $130,946,596 across 6 Biotechnology names. EXEL ranks #5 (4.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
1,639,968 | $78,669,264 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
90,206 | $18,009,627 | |
| 3 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
568,676 | $14,080,417 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
214,102 | $13,837,412 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
142,980 | $6,132,412 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
487 | $217,464 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,132,412 | 142,980 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $13,634,724 | 311,082 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $12,043,782 | 291,617 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $11,251,023 | 255,241 | Shares | Sole | 2025-08-14 | |
| 2024-03-31 | $2,113,251 | 89,054 | Shares | Sole | 2024-05-15 | |
| 2022-12-31 | $2,457,568 | 153,215 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $1,209,774 | 77,154 | Shares | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||